The US Polycystic Ovarian Syndrome Treatment Market is slated to reach US$ 100 Million at a CAGR of 3.9% between 2024. The present scenario is that of consumers driving as well as the accelerating pace of alteration in the healthcare vertical. This drives the digitally-enabled, seamlessly connected, and on-demand clinician-patient interactions. As such, patient-centric delivery transcending geographical barriers would be the epicenter going forward.
Prevalence of endocrine diseases in the US is on a rise as the country’s urban residents continue to bear the brunt of their sedentary lifestyles. Rising incidence of endometriosis, unexplained infertility and polycystic ovarian syndrome (PCOS) continues to alarm public health authorities across the US.
Measures undertaken by non-profit organizations and US health regulatory bodies are promoting the awareness of PCOS treatments. Also, therapies for diseases associated with PCOS are being developed to bear out the unmet clinical needs of people suffering from such complications.
Get Going With Sample Of US Polycystic Ovarian Syndrome Treatment Market Report! https://www.persistencemarketresearch.co/samples/14317
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Merck KGaA
How About Re-Inventing The Methodical Wheel In The US Polycystic Ovarian Syndrome Treatment Market? Switch Over To The “Methodology” Tab! https://www.persistencemarketresearch.co/methodology/14317
Despite this, the demand for PCOS treatment continues to incur a sluggish growth across the US. Persistence Market Research’s recent publication estimates that the US$ 230 Mn PCOS treatment market in the US will exhibit a moderate value CAGR of 3.9% to reach US$ 313.2 Mn by the end of 2024.
The foremost growth inhibitor for polycystic ovary syndrome treatment market in the US is pending approval of drugs at the FDA. The US FDA continues to prolong the approval for drugs on polycystic ovary syndrome treatment. And, this has severely lowered the production of effective medicines, thereby impacting the adoption of PCOS treatment.
Presently, no drugs have been approved by the FDA for direct treatment of PCOS. Physicians are thus providing drug prescriptions through off-label indications, which is incidentally diverting patients to generic drugs.
Titled as “Polycystic Ovary Syndrome Treatment Market: US Industry Analysis and Forecast, 2016-2024,” the report projects that in 2016, more than US$ 66 Mn worth of oral contraceptive drugs were consumed in the US polycystic ovary syndrome treatment market.
Keeping A Tab On Key Players In The US Polycystic Ovarian Syndrome Treatment Market? Go To “Purchase Now” To Decipher The Competitive Analysis In Our US Polycystic Ovarian Syndrome Treatment Market Report! https://www.persistencemarketresearch.com/checkout/14317
Through 2024, oral contraceptives will be exhibiting a steady revenue growth at 5.3% CAGR, and will account for nearly one-third share of market value. Besides, the demand for insulin sensitizing agents is expected to close in on number of oral contraceptives consumed in the US PCOS treatment market during this forecast period. Furthermore, growing preference to advanced drugs will also boost the consumption of aromatase inhibitors & SERMs, revenues from which will reach US$ 49 Mn by 2024-end.
More than 47% of US polycystic ovary syndrome treatment market will be accounted by drug sales through hospital pharmacies. With hospitals as the largest distribution channel, nearly US$ 150 Mn worth of PCOS drugs will be sold through these pharmacies.
Meanwhile, PCOS drug sales through e-commerce platforms are projected to showcase a value CAGR of 4.6%, higher than that of hospital pharmacies and other distribution channels such as fertility clinics, drug stores and over-the-top counters.
Access Related Reports-
Heel Pressure Injury Relieving Devices Market @ https://www.prnewswire.com/news-releases/heel-pressure-injury-relieving-devices-market-is-expected-to-reach-us-529-0-mn-in-terms-of-value-by-2026-end-persistence-market-research-895039264.html
Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – firstname.lastname@example.org